Allogene Therapeutics Inc (ALLO)
3.075
-0.12
(-3.61%)
USD |
NASDAQ |
Nov 08, 16:00
3.075
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Revenue (TTM)
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.043M |
| December 31, 2023 | 0.051M |
| September 30, 2023 | 0.055M |
| June 30, 2023 | 0.061M |
| March 31, 2023 | 0.125M |
| Date | Value |
|---|---|
| December 31, 2022 | 0.156M |
| September 30, 2022 | 75.85M |
| June 30, 2022 | 75.85M |
| March 31, 2022 | 75.80M |
| December 31, 2021 | 114.09M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.043M
Minimum
Mar 2024
114.09M
Maximum
Dec 2021
34.21M
Average
0.1405M
Median
Revenue (TTM) Benchmarks
| ANI Pharmaceuticals Inc | 538.95M |
| AIM ImmunoTech Inc | 0.201M |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 38.05M |
| Armata Pharmaceuticals Inc | -- |